Chemotherapy of ovarian and breast cancer with Taxol
Deutsche Medizinische Wochenschrift 121(50 Suppl): 1-12
1996
ISSN/ISBN: 0012-0472 PMID: 9022362 Document Number: 455632
Document emailed within 1 workday
Related Documents
Ozols, R.F. 2000: Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer Seminars in Oncology 27(3 Suppl 7: 3-71992: Taxol improves outlook for lung, breast, and ovarian cancer Oncology 6(8): 16
Kmietowicz, Z. 2000: NICE approves Taxol for ovarian cancer Bmj 320(7245): 1293
Ezcurdia, L.; Jovtis, S.L.; Mickiewicz, E.; Temperley, G.; Rondinón, M.; Blajman, C.; Cóppola, F.S.; Lewi, D.; Cazap, E.; Breier, S.; Fasce, H.; Fein, L.; Polera, J.; Triguboff, E.; Uranga, G.; Pasccón, G.; Luchina, A.M.; Martínez, C.A.; Politi, P.M.; Rubio, G.; Alvarez, A.M. 1997: Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group Seminars in Oncology 24(5 Suppl. 15): S15
Sen, S.; Zocchetti, A.; Beccaglia, P.; Balconi, G.; Erba, E.; D'Incalci, M. 1994: Heterogeneous interaction of interferon-beta and taxol in human ovarian cancer cells in vitro European Journal of Cancer 30a(6): 892-893
Frankel, A.; Buckman, R.; Kerbel, R.S. 1997: Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids Cancer Research 57(12): 2388-2393
Sledge, G.W.; Robert, N.; Sparano, J.A.; Cobeligh, M.; Goldstein, L.J.; Neuberg, D.; Rowinsky, E.; Baughman, C.; McCaskill-Stevens, W. 1994: Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience Seminars in Oncology 21(5 Suppl 8: 15-18
Du Bois, A.; Lück, H.J.; Meier, W.; Möbus, V.; Costa, S.; Richter, B.; Warm, M.; Bauknecht, T.; Schröder, W.; Olbricht, S.; Nitz, U.; Jackisch, C. 1997: Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase IIi trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group Seminars in Oncology 24(5 Suppl 15: S15
Friedenson, B.; Friedenson, H. 2002: Genetic testing for breast and ovarian cancer for women with a family history of breast cancer: weighing conflicting evidence about oral contraceptives Medgenmed: Medscape General Medicine 4(3): 3
Stamatovic, L.; Susnjar, S.; Gavrilovic, D.; Minic, I.; Ursulovic, T.; Dzodic, R. 2018: The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(5): 1273-1280
Donegan, W.L. 1992: Recent trends in the management of breast cancer. 3. Controversies in the use of adjuvant chemotherapy, hormonotherapy and radiotherapy for breast cancer Canadian Journal of Surgery. Journal Canadien de Chirurgie 35(4): 371-377
Murakami, F.; Kiyozuka, Y.; Nishimura, H.; Imamura, K.; Yakushiji, M.; Noda, T.; Adachi, S.; Ito, K.; Tamori, N.; Shintani, M. 1993: Etoposide/cis-platinum (CDDP) combined chemotherapy for ovarian cancer: evaluation of optimum schedule for CDDP administration in chronic continuous exposure of ovarian cancer cells to low-dose etoposide in vitro Nihon Sanka Fujinka Gakkai Zasshi 45(2): 125-132
Bhat, N.; Perera, P.Y.; Carboni, J.M.; Blanco, J.; Golenbock, D.T.; Mayadas, T.N.; Vogel, S.N. 1999: Use of a photoactivatable taxol analogue to identify unique cellular targets in murine macrophages: identification of murine CD18 as a major taxol-binding protein and a role for Mac-1 in taxol-induced gene expression Journal of Immunology 162(12): 7335-7342
Chen, G.; Teicher, B.A.; Frei, E. 1996: Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells Anticancer Research 16(6b): 3499-3505
Jacobs, I.J.; Smith, S.A.; Wiseman, R.W.; Futreal, P.A.; Harrington, T.; Osborne, R.J.; Leech, V.; Molyneux, A.; Berchuck, A.; Ponder, B.A. 1993: A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus Cancer Research 53(6): 1218-1221
2006: Comparative effects of the administration period of adjuvant chemotherapy using doxifluridine (5'-DFUR) for 1 year versus 3 years after breast cancer surgery by the Shimane Breast Cancer Study Group Anticancer Research 26(1b): 591-597
2004: Adjuvant chemotherapy for early breast cancer: protocol and nonprotocol treatment options. Proceedings of a national research leader think tank and 3 regional breast cancer update working group meetings. July-October 2003 Oncology 18(4 Suppl. 1): 5-22
Willemse, P.H.; Sleijfer, D.T.; Brouwers, T.M.; van der Ploeg, E.; Doorenbos, H. 1981: Amenorrhea following chemotherapy for the treatment of breast carcinoma: a suitable criterion of ovarian insufficiency? Nederlands Tijdschrift Voor Geneeskunde 125(20): 775-779
Ozols, R.F.; Young, R.C. 1991: Chemotherapy of ovarian cancer Seminars in Oncology 18(3): 222-232
Camci, C.; Balat, O. 2002: Neoadjuvant chemotherapy in ovarian cancer European Journal of Gynaecological Oncology 23(5): 437-441